At this year’s International Pharmaceutical Federation (FIP) World Congress in Copenhagen, Carina Dantas, CEO of SHINE 2Europe, spotlighted the transformative potential of the RadioVal project, which is reshaping the future of AI-driven breast cancer diagnosis.
Dantas underscored that RadioVal’s mission goes beyond technology. “Validation is not just about algorithms, it’s about people,” she stressed. The project is working to ensure that artificial intelligence in breast cancer care is accurate, equitable, transparent, and trustworthy.
By testing AI tools across diverse countries and healthcare systems, RadioVal tackles one of the biggest challenges in digital health: ensuring innovations work for all populations, regardless of geography, gender, or socioeconomic background. This validation guarantees that models are not only technically sound but also inclusive and ethically robust.
“RadioVal demonstrates that innovation in cancer diagnosis must go hand in hand with validation in real-world, diverse contexts,” said Dantas. “This is how we ensure trust and equity in AI that touches people’s lives at their most vulnerable moments.”
The FIP World Congress—welcoming a record-breaking 3,455 participants from 120 countries—offered the ideal platform to amplify RadioVal’s vision. The project was recognized as a leading example of how European collaboration can set global standards in combining technical excellence, ethics, and inclusivity for healthcare innovation.
